Ultragenyx’s Phase 3 program for Angelman syndrome failed to meet both the primary and key secondary endpoints, cutting short expectations for its apazunersen (GTX-102) RNA-targeting approach. The company said it will evaluate significant cost cuts and consider next steps after the Aspire trial did not achieve the planned Bayley-4 cognitive raw score change-from-baseline goal or the Multidomain Responder Index response target.